Key result
Atrial natriuretic peptide, but not NT-proANP, successfully detected left atrial dilatation in horses, with significantly higher concentrations in affected horses (median 366 vs 31 pg/ml; P=0.02).
Why the study?
Does ANP or NT-proANP better detect left atrial dilatation in horses?
Observational (n=47)
Does ANP or NT-proANP better detect left atrial dilatation in horses?
ANP, but not NT-proANP, is a suitable biomarker for detecting left atrial dilatation in horses, though it is less stable when stored at -20°C.
ANP may detect equine left atrial dilatation where NT-proANP does not; leaves open need for species-specific NT-proANP validation before clinical use.
REASONS FOR PERFORMING STUDY: Studies on the use of atrial natriuretic peptide (ANP) as a biomarker for left atrial dilatation in horses have produced variable results. Few have been performed, and the results may have been influenced by ANP instability, differences in sampling protocol and changes in the assay over time. N-Terminal proANP (NT-proANP) is a more stable molecule and might be a good alternative for clinical use. OBJECTIVES: To compare ANP and NT-proANP in terms of the detection of left atrial dilatation and to determine the influence of sample storage at temperatures of -80 and -20°C. STUDY DESIGN: Prospective clinical study. METHODS: Atrial natriuretic peptide and NT-proANP concentrations were compared between healthy horses (Group 1, n = 20), horses with mitral valve regurgitation and a normal atrial size (Group 2, n = 11) and horses with mitral valve regurgitation associated with left atrial dilatation (Group 3, n = 16). The ANP concentration was measured with an equine enzyme-linked immunosorbent assay and the NT-proANP concentration with an enzyme-linked immunosorbent assay developed for use in human patients. Samples were stored at -20 and -80°C and analysed within 7 months. RESULTS: The NT-proANP concentrations were not significantly different between the groups. Horses in Group 3 had a significantly higher ANP concentration (median 366 pg/ml; interquartile range [IQR] 74-2000 pg/ml) compared with horses in Group 1 (median 31 pg/ml; IQR 31-333 pg/ml) or Group 2 (median 31 pg/ml; IQR 31-1152 pg/ml; P = 0.02). The ANP cut-off value for detection of left atrial dilatation was 52 pg/ml (sensitivity 81%; specificity 84%) for sample storage at -80°C, and 44 pg/ml (sensitivity 69%; specificity 84%) for storage at -20°C. A larger decrease in ANP (45 ± 126 pg/ml) than in NT-proANP (10 ± 31 pg/ml) was found associated with sample storage at -20 instead of -80°C. CONCLUSIONS: Atrial natriuretic peptide, but not NT-proANP, can be used to detect left atrial dilatation in horses. Atrial natriuretic peptide is less stable than NT-proANP when samples are stored at -20°C. Atrial natriuretic peptide is a more suitable biomarker of left atrial dilatation in horses than NT-proANP.
No takes yet. Share an insight, caveat, or question.
Vekens et al. (2014) conducted an observational in Left atrial dilatation in horses (n=47). Atrial natriuretic peptide (ANP) and NT-proANP measurement vs. Healthy horses and horses with normal atrial size was evaluated on Detection of left atrial dilatation via ANP and NT-proANP concentrations (p=0.02). Atrial natriuretic peptide, but not NT-proANP, successfully detected left atrial dilatation in horses, with significantly higher concentrations in affected horses (median 366 vs 31 pg/ml; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: